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Abstract
Background: There is scarce knowledge on the prevalence of diseases caused by non-tuberculous mycobacteria
(NTM) in Pakistan. In the absence of culture and identification, acid-fast bacilli (AFB) causing NTM disease are liable
to be misinterpreted as tuberculosis (TB). Introduction of nucleic acid amplification testing for Mycobacterium
tuberculosis complex (MTBC) offers improved diagnostic accuracy, compared with smear microscopy, and also
assists in differentiating MTBC from other mycobacteria. This study aimed to investigate the prevalence of NTM
among patients investigated for TB and describe NTM disease and treatment outcomes at a tertiary care hospital in
Pakistan.
Methods: This is a retrospective study, data on NTM isolates among culture-positive clinical samples over 4 years
(2016–19) was retrieved from laboratory records. Information on clinical specimens processed, AFB smear results,
and for the AFB positive isolates, results of species identification for MTBC, and for NTM isolates, results of species
characterization and drug susceptibility testing was collected. Additional clinical data including patient
characteristics, treatment regimens, and outcomes were collected for patients with NTM disease treated at Gulab
Devi Hospital, Lahore.
Results: During the study period, 12,561 clinical specimens were processed for mycobacterial culture and 3673
(29%) were reported positive for AFB. Among these 3482 (95%) were identified as MTBC and 191 (5%) as NTM.
Among NTM, 169 (88%) were isolated from pulmonary and 22 (12%) from extrapulmonary specimens. Results of
NTM speciation were available for 60 isolates and included 55% (n = 33) M. avium complex and 25% (n = 15) M.
abscesses. Among these patients, complete clinical records were retrieved for 12 patients with pulmonary disease
including nine infected with M. avium complex and three with M. abscessus. All 12 patients had a history of poor
response to standard first-line anti-TB treatment. Ten patients were cured after 18 months of treatment, whereas,
one with M. abscessus infection died and another was lost to follow up.
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Conclusion: In TB endemic areas, NTM can be misdiagnosed as pulmonary TB leading to repeated failed anti-TB
treatment and increased morbidity, emphasizing the need for improved diagnosis.
Keywords: Non-tuberculous mycobacteria, NTM pulmonary disease, NTM treatment, Mycobacterial species,
Pulmonary tuberculosis, Acid-fast microscopy
Background
Non-tuberculous mycobacteria (NTM) are ubiquitous
environmental acid-fast bacilli (AFB). Although NTM
are not obligate pathogens, they share with M. tubercu-
losis complex (MBTC) the features of hardiness, hydro-
phobicity, aerosolization, and intracellular pathogenicity.
Even though the lung is the most common organ in-
volved, NTM can cause disease in other organs of the
body [1]. The commonest extrapulmonary organs in-
volved are lymph nodes, skin/soft tissue, and dissemi-
nated disease [2]. The probability of NTM disease
increases with the extent of environmental exposure, im-
munosuppression, and pulmonary NTM disease often
occurs with co-existent chronic lung diseases [3–5].
However, pulmonary NTM disease can also be seen in
previously well individuals [6]. It is usually difficult to
distinguish tuberculosis (TB) from NTM lung disease
based on clinical and radiological features [6]. The pul-
monary disease caused by NTM, is likely to be misinter-
preted as pulmonary TB based on AFB microscopy in
the absence of culture and species identification [7].
There are increasing reports of NTM worldwide [8–13]
and the likelihood that a substantial number of sputum
smear-positive cases might be due to NTM. In high TB
endemic countries, the chances of missing NTM species
are higher because of the higher pre-test probability of
TB, scarce resources, limited laboratory capacity, and
overburdened health systems. The information regarding
their true incidence and prevalence in these countries is
scarce [14]. This study aimed to investigate the preva-
lence of NTM and different NTM strains among the pa-
tients investigated for TB and to describe the disease
characteristics and treatment outcome of patients with
NTM at a tertiary care hospital in Pakistan.
Methods
Study setting
Pakistan is a high TB burden country. For diagnosis of
TB, AFB microscopy services are available at more than
1500 health facilities across the country. Automated nu-
cleic acid amplification (Xpert MTB/RIF) assay was in-
troduced in 2011 at few health facilities in Pakistan. The
testing facilities were gradually scaled up and were made
available at more than 300 health facilities by 2019. Cul-
ture and drug sensitivity testing services are limited to
only a few centers in the country. The study was
conducted at Gulab Devi Hospital. It is a private not-
for-profit large tertiary care hospital located in Lahore,
the capital city of the country’s largest province. Gulab
Devi hospital is a specialized TB Hospital and is
equipped with Xpert MTB/RIF assay and TB culture fa-
cilities. Diagnosis of pulmonary TB is routinely made by
sputum smear microscopy, and culture is not performed
on all samples [15]. Culture is usually requested by the
physicians when patients are not responding to standard
anti-TB treatment to see if the patient is infected with
drug-resistant strains. For extrapulmonary TB and other
difficult-to-diagnose cases, culture may be requested for
diagnosis.
Laboratory facilities for NTM speciation were estab-
lished at the national TB reference laboratory Islamabad
in 2017 and are offered free of cost for patients seeking
care from the linked facilities. Facilities for drug suscep-
tibility testing for NTM, are only offered by one refer-
ence laboratory in the private sector, and only selected
patients are referred there to get a susceptibility pattern.
Study design and data collection
This is a retrospective study. Routinely collected data
was used for the study. All clinical isolates which were
reported culture positive for AFB between 2016 and
2019 were included in the study. Culture results, Species
identification report, drug susceptibility testing reports,
and follow-up data were obtained from laboratory regis-
ters and patient files.
Laboratory methods
Specimens were processed with Petroff’s method using
the NALC-NaOH method at a final concentration of 4%
NaOH [16]. Extrapulmonary samples from sterile sites
were concentrated without decontamination. Processed
sediment was inoculated on two slopes of Lowenstein-
Jensen medium and a BACTEC Mycobacteria Growth
Indicator Tube 960 (MGIT960; Becton Dickinson,
Sparks, MD, USA). Smears of the processed sediment
were stained with auramine and examined using a light-
emitting diode fluorescence microscope [16].
All culture isolates were first examined for AFB on
smear. All AFB positive isolates were tested for detection
of MPT64 antigen, specific for MBTC, using the TB Ag
MPT64 rapid test kit (SD Bioline, Kyonggi, Korea) [16].
All culture isolates which were AFB positive but negative
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for MBTC were shipped to the national TB reference la-
boratory Islamabad for NTM identification. At the na-
tional TB reference laboratory, freshly grown
subcultures were tested again for MTBC. Culture iso-
lates negative for MTBC were then processed first for
primary identification and characterization of species for
the most common mycobacterial species using reverse
hybridization-based line probe assay, GenoType Myco-
bacterium CM (Hain Lifescience, Nehren Germany).
Drug susceptibility testing was done at Aga Khan Uni-
versity Hospital, Karachi. Broth microdilution was used
to perform drug susceptibilities using 96 well sensitive
plates (TREK Diagnostic Systems Ltd., UK) as per the
manufacturer’s recommendations. Susceptibility data
thus obtained was interpreted according to the Clinical
and Laboratory Standards Institute’s criteria [17].
Statistical analysis
The data were entered into SPSS version 20 and cleaned
for further analysis. A chi-square test was performed to
show the differences between the pulmonary and extra-
pulmonary patient groups. A p-value of less than 0.05
was considered statistically significant.
Results
A total of 12,561 samples were received for culture dur-
ing 2016–2019 (Fig. 1). Among these 2568 (20%) sam-
ples were positive for AFB on smear examination while
9993 (80%) were negative for AFB on smear. Among the
smear-positive samples, 2328 (92%) were culture posi-
tive, 2212 (95%) of these were identified as MTBC, while
116 (5%) were declared NTM. Among the smear-
negative samples, 1345 (14%) were culture positive, 1270
(94%) were MTBC and 75 (6%) were NTM.
Species identification
Species identification was done for 60/191 samples (54
pulmonary and 6 extrapulmonary) as shown in Fig. 1.
Among pulmonary samples, M. avium complex was
identified in the majority 33/54 (61%), followed by
Fig. 1 Flow diagram showing proportion of non-tuberculous mycobacteria isolated from AFB smear-positive and AFB-smear negative pulmonary
and extrapulmonary specimens processed for culture from 2016 to 2019. AFB = acid fast bacilli, P = pulmonary, ExP = extrapulmonary, MTBC =
Mycobacterium tuberculosis complex, NTM = Non-tuberculous mycobacteria, MAC =Mycobacterium avium complex
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M. abscessus 13/53 (24%), M. fortuitum 3/54 (5.5%),
M. kansasii 3/54 (5.5%), M. gordonae 1/54 (2%) and
M. szulgai 1/54 (2%). In 6 extrapulmonary samples,
M. abscessus was isolated in 2 (33%) while M. fortuitum
was isolated in 4 (67%) samples. Table 1 shows year wise
data of the total cultures applied, and MTBC, and NTM
isolated from the AFB positive isolates. NTM Species
identification was done for 1/43 (2%), 12/70 (17%), 28/50
(56%), and 19/28 (68%) of NTM isolates reported respect-
ively in 2016–2019.
Patient characteristics
Table 2 shows the characteristics of patients with
culture-positive pulmonary (n = 169) and extrapulmon-
ary disease (n = 22) caused by NTM. Human immuno-
deficiency virus (HIV) status was available for 22 cases
and all were negative.
Among the pulmonary NTM disease, there was a male
preponderance (61%), whereas extrapulmonary NTM dis-
ease was more common in females (68%). Among the pul-
monary NTM disease, 110/169 (65%) had received anti-TB
treatment before their specimens were tested for culture. In
these cases, culture was requested by the physicians to rule
out drug resistance TB. Among these 82/110 (75%) had re-
ceived 2 months of treatment with isoniazid (H), rifampicin
(R), ethambutol (E), and pyrazinamide (Z) and 4 months
with RHE. Streptomycin was given in addition to 28/110
(25%) patients during the first 2 months. In extrapulmonary
NTM disease, the majority (15/22, 68%) were never treated
for TB. In these cases, culture was requested as a part of
diagnostic work-up. Among 22 NTM reported in the extra-
pulmonary specimens, the disease sites included lymph
nodes in 7, pleural fluids in 8, and perinephric abscess in 1.
Disease sites were not specified in 6 samples, labeled as pus
(3) and other tissue samples (3).
Case-based data
Case-based data with complete medical records and
follow-up details were available from only12 patients as
shown in Table 3.
Symptoms and radiology
All 12 patients for whom complete data were available
were females suffering from pulmonary disease, with
concomitant involvement of lymph nodes in one patient.
All patients presented with fever, productive cough, and
weight loss. Hemoptysis was present in 3/12 patients,
but none had any life-threatening episodes. All had ex-
tensive fibro-cavitary disease on radiology and long-term
oxygen therapy was required by only one patient.
Comorbid conditions
Among these patients, concomitant diabetes was present
in 5/12 (42%), chronic liver disease in 3/12 (25%). Two
(17%) patients had both diabetes and chronic liver
disease.
Laboratory investigations
Sputum specimens from all 12 patients were positive for
AFB smear and MTB was not detected on Xpert MTB/
RIF assay. Mycobacterial cultures from these patients’
specimens yielded AFB positive isolates, negative for
MTBC. Nine of these patients had M.avium complex
and 3 had M. abscessus disease.
Phenotypic drug susceptibility testing
All nine M. avium complex isolates were tested for clari-
thromycin, amikacin, and moxifloxacin, and among
these only one case was resistant to amikacin. All three
M. abscessus isolates were sensitive to clarithromycin,
moxifloxacin, and linezolid.
Treatment
All cases of M. avium complex were treated with etham-
butol, rifampicin, isoniazid (RHE combination as per
weight), clarithromycin (500 mg BD), and amikacin (500
mg BD) IM thrice weekly for initial 6 months (except for
one case resistant to amikacin, who was treated without
it). Treatment was given for 18 months. Isoniazid was
added in therapy as rifampicin and ethambutol were
only available in combination with isoniazid. All cases of
M. abscessus were treated with moxifloxacin and linezo-
lid. Among these, patient 10 received RHE and clarithro-
mycin initially till results of species identification and
drug susceptibility testing became available, patient 11
stopped amikacin after 3 months due to side effects, and
patient 12 stopped clarithromycin after 2 months due to
resistance.
Table 1 Specimens processed and prevalence of non-tuberculous mycobacteria among patients investigated for tuberculosis
Year 2016 2017 2018 2019 Total
Culture processed 1934 4781 3173 2673 12,561
Culture Positive for AFB 1165 875 944 689 3673
MPT64-positive (MTBC) n (%) 1122 (96) 805 (92) 894 (95) 661 (96) 3482 (95)
MPT64-negative (NTM) n (%) 43 (4) 70 (8) 50 (5) 28 (4) 191 (5)
NTM Speciation performed n (%) 1 (2) 12 (17) 28 (56) 19 (68) 60 (31)
AFB Acid fact bacilli, MTBC Mycobacterium tuberculosis complex, NTM Non-tuberculous mycobacteria, n number
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Follow-ups
All 12 patients were monitored for treatment response
and adverse drug reactions. Patients were called weekly
for the first 2 months and then monthly for the rest of
the treatment period for complete blood picture, renal
and liver function tests. Visual acuity and ECGs were
checked on the first follow-up only. These patients were
followed-up by the doctor at 2, 4, 6, and 9 months and if
culture-negative, the last culture was performed at the
end of the treatment.
Treatment response
No serious side effects were observed during the treat-
ment. All patients started improving symptomatically
after 2 months of treatment. One patient was culture-
negative at 4 months while nine more became culture-
negative at 6 months. Two patients remained culture-
positive after 6 months of treatment. Among those two
who were culture-positive at 6 months, one remained
culture-positive at 9 months and did not come for fur-
ther follow-ups after 12 months of treatment. The sec-
ond one, who was culture-positive at 6 months, expired
during the eighth month of treatment, This patient de-
veloped respiratory failure type 1 and required long-
term oxygen therapy, developed left-sided pneumo-
thorax which resolved with treatment, but respiratory
failure worsened with an increase in requirement for
oxygen therapy. The patient expired at home after 1
month of discharge. Ten patients who completed treat-
ment remained culture-negative after conversion and
were declared cured at the end of the treatment.
Generally, the disease was more severe among patients
infected with M. abscessus. Symptoms in these patients
took longer to resolve and culture conversion was late,
where 2/3 of these patients remained culture-positive at
6 months. The treatment outcome was also less favor-
able in these patients.
Discussion
Our study shows that 5% of the culture-positive patients
who were initially presumed to have TB or were treated
for TB, were infected with NTM. More than 65 % of
these patients had received anti-TB treatment, and a
small but significant proportion had received multiple
cycles of anti-TB therapy. These findings show that a
substantial number of patients with NTM disease in the
high TB prevalence settings with large populations are
incorrectly diagnosed as TB, leading to inappropriate
Table 2 Characteristics of patients with positive culture for non-tuberculous mycobacteria
Pulmonary Extrapulmonary p-value
Total Patients, n/N (%) 169/191 (88) 22/191 (12)
Median Age, years (Range) 45d (6–75) 21 (6–90) < 0 .001
Gender, n/N (%)
Male 103/169 (61) 7/22 (32) 0.009
Female 66/169 (39) 15/22 (68)
Treatment historya, n/N (%)
Single cycle of RHEZb 82/169 (48) 2/22 (9) < 0 .001
One or more cycles of RHEZSc 28/169 (17) 0/22 (0)
Unknown 34/169 (20) 5/22 (23)
Not Treated 25/169 (15) 15/22 (68)
HIV Status, n/N (%)
Negative 22/169 (13) 0/22 (0) 0.936
Unknown 147/169 (87) 22/22 (100)
Sites involved, n/N (%)
Lung 169/169 (100) –
Lymph nodes – 7/22 (32)
Pleural fluid – 8/22 (36)
Pus – 3/22 (14)
Tissue – 3/22 (14)
Perinephric fluid – 1/22 (4)
n number, N total number, % percentage, MAC Mycobacterium avium complex
aPrevious anti-tuberculous treatment
bRHEZ = rifampicin + isoniazid + ethambutol + pyarzinamide
cRHEZPS = rifampicin + isoniazid + ethambutol + pyrazinamide + streptomycin
dData from163 patients, missing data for age for 3 patients
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treatment, unfavorable outcomes, and increased morbid-
ity. In settings with limited access to culture or nucleic
acid amplification testing, the risk is further augmented
when patients fail to respond to standard anti-TB ther-
apy with a likelihood of prompting empirical treatment
recommended for drug-resistant TB. Empirical treat-
ment with second-line anti-TB drugs in such scenarios
would cause further delays in the correct diagnosis and
increased morbidity due to adverse drug effects. This
highlights the importance of confirmation of AFB seen
on microscopy as MTBC with nucleic acid amplification
testing, and further investigations including culture with
species identification for all cases reported positive for
AFB microscopy but are negative for MTBC. Diagnosis
of NTM infection requires repeated cultures as in the
international guidelines for NTM lung disease [18],
highlighting the need to strengthen laboratory facilities
for mycobacterial cultures. MPT64 based tests are
shown to be a rapid and reliable method for MTBC
identification in liquid culture assays [19]. A small mi-
nority of MTBC isolates are not detected by MPT64 as-
says due to deletion or mutation of the MPT64 gene
(absent from some M. bovis BCG strains) [20–22], or
due to low MPT64 concentrations in early cultures or
mixed cultures [23, 24]. The low cost and simplicity of
MPT64 assays would outweigh the small reduction in
sensitivity in most settings and performing nucleic acid
amplification tests on MPT64-negative isolates might
further improve sensitivity [22].
M. avium complex is reported to be the predominant
species in the pulmonary NTM cases, constituting up to
80% of NTM infections [25], however, in our population,
M. avium complex was isolated in 60% of pulmonary
cases, whereas M. abscessus was reported in 24% of
cases. This difference in prevalent NTM causing pul-
monary disease could have been due to our small sample
size. It has been reported previously that M.abscessus is
shown to be more prevalent among patients with cystic
fibrosis [26]. None of the patients in our cohort was
known to have cystic fibrosis implying that M. abscessus
should be considered a pathogen among non-cystic fi-
brosis patients as well. Disease caused by M. abscessus is
more aggressive leading to irreversible loss of lung func-
tion [27], and timely and accurate diagnosis and treat-
ment could lead to preservation of lung function.
Studies have shown a female preponderance for M.
avium pulmonary infections. Older females of thin body
type with otherwise healthy lungs are shown to have M.
avium complex infection mainly in the middle portions
of their lungs. In contrast, we report a male preponder-
ance (61%) in our study population. Smoking is a known
risk factor for chronic obstructive lung disease (COPD),
and COPD could predispose to NTM infections and it
increases the decline in lung function in COPD patients
[28–30]. Smoking is much more prevalent among males
as compared to females in Pakistan and this comorbidity
among males could be a possible explanation for ob-
served male predominance, but we do not have enough
data to test this hypothesis.
Even though NTM disease is said to occur more fre-
quently in the HIV-positive population, there were no
HIV-positive patients among the 20% tested for HIV in
our cohort. Considering the low prevalence of HIV in
Pakistan [31], the findings from this study may be con-
sidered applicable to HIV-negative populations.
We studied clinical records available for a subset of 12
patients. Drug susceptibility results were available for all
12 patients and the susceptibility profile reported was
similar for nine patients with NTM disease caused by M.
avium complex and three with M.abscessus. Uniform
drug susceptibility profile for a particular NTM species
suggests that patients can be treated based on speciation
results of NTM. We also studied the clinical records of
these 12 patients for treatment regimen, clinical and
bacteriological response, and treatment outcomes. Treat-
ment success was high for patients with M. avium com-
plex despite fibro-cavitary disease as compared to other
studies [32, 33]. All patients reported good clinical re-
sponse with resolution of symptoms by the end of the
second month of treatment and were culture negative by
the end of the sixth month of treatment. One reason
could have been the continuation of quadruple therapy
and the uninterrupted use of intramuscular amikacin for
the initial 6 months. However, due to the small sample
size, a firm conclusion cannot be made. Compared to M.
avium complex, patients with M. abscessus although
younger, showed a relatively poor clinical response and
unfavorable outcomes, and culture conversion took a
longer time as shown in the previous studies [34].
Prevalence of diabetes (5/12, 42%) was higher in our pa-
tient group compared to the general population [35]
showing that patients with diabetes may be more suscep-
tible to NTM infections. Our findings are consistent with
other studies showing increased susceptibility to non-
respiratory NTM infections in patients with diabetes mel-
litus [36, 37]. Diabetes is a multifactorial metabolic condi-
tion with a complex etiopathology. Exposure to chronic
hyperglycemic conditions can induce oxidative stress, in-
flammatory changes, and immune dysfunction, contribut-
ing to increased susceptibility to bacterial infections along
with a poorer prognosis [38–40]. The prevalence of dia-
betes is much higher in the resource-poor regions where
TB and environmental NTM infections are both highly
endemic and where diagnostic facilities are rudimentary
[41–43]. The increased susceptibility to bacterial patho-
gens in diabetes represents an important complication
given the growing combined burden of communicable
and non-communicable conditions [38, 44].
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Our study has some limitations. First, this study was
conducted in a specialized tertiary care hospital, and the
possibility of a higher prevalence of NTM compared to
the general population cannot be excluded because of a
higher proportion of patients with a history of previous
TB treatment, poor response to TB treatment or diffi-
culty in diagnosis, seeking care from this hospital. Sec-
ondly, the analysis was based on patient samples
selected for culture, and this could have added the selec-
tion bias. Thirdly, because of the retrospective nature of
the study, the information collected and clinical record
retrieved were not complete, limiting the generalizability
of the findings. Lastly, a comparison of treatment out-
comes was not possible between the patients diagnosed
promptly and those who faced diagnostic and treatment
delays due to misdiagnosis. This limitation can be ad-
dressed in future prospective studies to compare the
outcomes between these two groups and to see the im-
pact of diagnostic delays in the initiation of treatment in
NTM disease. Despite these limitations, the findings
from this study add to the information on the prevalence
of NTM disease in low HIV and high TB endemic set-
tings and highlight the need to improve diagnosis and
treatment of NTM disease.
Conclusion
This study shows a 5% prevalence of NTM among pre-
sumptive TB patients investigated for tuberculosis in a
tertiary care hospital. Considering the high prevalence of
TB in Pakistan, the risk of patients being misdiagnosed
and receiving inappropriate treatment can be substantial.
Our study highlights the need to strengthen and expand
clinical and laboratory services to diagnose and manage
diseases caused by NTM in parallel with MTBC.
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